Fennec Pharmaceuticals Inc (FENC)

NASDAQ
Currency in USD
6.425
-0.085(-1.31%)
Real-time Data
FENC Scorecard
Full Analysis
Impressive gross profit margins
Fair Value
Day's Range
6.4256.636
52 wk Range
3.96011.490
Key Statistics
Edit
Prev. Close
6.51
Open
6.52
Day's Range
6.425-6.636
52 wk Range
3.96-11.49
Volume
8.12K
Average Volume (3m)
75.67K
1-Year Change
-34.51%
Book Value / Share
-0.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FENC Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
12.600
Upside
+96.11%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year
Show more

Fennec Pharmaceuticals Inc Company Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.06 beat -$0.13 forecast; revenue of $7.92M slightly exceeded expectations
  • Full-year 2024 net product sales reached $29.6M, up 39% from 2023, driven by PedMark adoption
  • Cash position strong at $26.6M; company maintains 93.52% gross profit margins
  • European expansion planned for 2025 with UK and German launches; Japan trial results expected by fall
  • Stock up 0.15% pre-market; analysts set $10-$15 price targets, near current fair value
Last Updated: 2025-03-10, 09:32 a/m
Read Full Transcript

Compare FENC to Peers and Sector

Metrics to compare
FENC
Peers
Sector
Relationship
P/E Ratio
−2,530.4x−0.8x−0.5x
PEG Ratio
−25.490.000.00
Price/Book
−32.2x0.7x2.6x
Price / LTM Sales
3.7x19.1x3.0x
Upside (Analyst Target)
99.7%250.0%56.4%
Fair Value Upside
Unlock32.8%9.9%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.600
(+96.11% Upside)

Earnings

Latest Release
Mar 10, 2025
EPS / Forecast
-0.06 / -0.13
Revenue / Forecast
7.92M / 7.88M
EPS Revisions
Last 90 days

FAQ

What Is the Fennec Pharma (FENC) Stock Price Today?

The Fennec Pharma stock price today is 6.425

What Stock Exchange Does Fennec Pharma Trade On?

Fennec Pharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Fennec Pharma?

The stock symbol for Fennec Pharma is "FENC."

What Is the Fennec Pharma Market Cap?

As of today, Fennec Pharma market cap is 175.35M.

What is Fennec Pharma Earnings Per Share?

The Fennec Pharma EPS is -0.003.

What Is the Next Fennec Pharma Earnings Date?

Fennec Pharma will release its next earnings report on May 08, 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.